Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
Condition: Primary Immunodeficiency Diseases (PID) Intervention: Drug: Cutaquig Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy & Immunology | Cancer & Oncology | Hematology | Pediatrics | Primary Immunodeficiency Disease | Research